Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System

The molecular adsorbent recycling system (MARS) represents a cell-free, extracorporeal, liver assistance method for the removal of both albumin-bound and water-soluble endogenous toxins. The aim of the present study was to evaluate the short- and long-term removal capacity and selectivity of the different inbuilt dialysers and adsorption columns (uncoated charcoal, anion exchanger resin). Levels of endogenous toxins and parameters of hepatic synthesis and necrosis were therefore monitored before, during and after the MARS treatment phase in 10 patients. Moreover, blood and dialysate clearances of urea, creatinine, bilirubin and bile acids were determined during a single treatment. The significant increasing time course of total bilirubin blood levels before the start of the treatment could be stopped and reversed in a significant decreasing time course. The removal rates of urea nitrogen, bilirubin and bile acids during a single treatment amounted to 55.5 ± 4.0, 28.3 ± 3.9, and 55.4 ± 4.0% (mean ± SEM), respectively. The efficacy of removal of albumin-bound toxins sharply declined early after initiation of the treatment to become negligible after 6 h. In conclusion, both albumin-bound and water-soluble toxins are adequately removed by the MARS. Our data suggest that the rate and efficacy of removal of albumin-bound toxins are related to both the strength of the albumin binding and the saturation of the adsorption columns.

[1]  J. O’Beirne,et al.  Liver support. , 2005, The International journal of artificial organs.

[2]  F. Nevens,et al.  The Molecular Adsorbent Recirculating System in patients with severe liver failure: clinical results at the K.U. Leuven. , 2002, Liver.

[3]  T. Hassanein,et al.  The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. , 2002, Artificial organs.

[4]  V. Sørensen,et al.  Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute‐on‐chronic liver failure , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  R. Bartlett,et al.  Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. , 2001, Surgery.

[6]  Ana Ivelisse Avilés,et al.  Linear Mixed Models for Longitudinal Data , 2001, Technometrics.

[7]  P. Berloco,et al.  Use of MARS in the Treatment of Acute Liver Failure: Preliminary Monocentric Experience , 2001 .

[8]  P. Sorkine,et al.  Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure , 2001, Critical care medicine.

[9]  S. Ash Biocompatibility of sorbent suspension dialysis in cirrhotic patients with hepatic encephalopathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  S. Mitzner,et al.  Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. , 2001, Zeitschrift fur Gastroenterologie.

[11]  C. Freise,et al.  Artificial liver support devices for fulminant liver failure. , 2001, Clinics in liver disease.

[12]  R. Cortesini,et al.  Use of MARS in the treatment of acute liver failure: preliminar monocentric experience. , 2001, Transplantation proceedings.

[13]  S. Mitzner,et al.  Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. , 2001, Journal of the American Society of Nephrology : JASN.

[14]  K. Böker,et al.  Akutes Leberversagen , 2001, Der Internist.

[15]  L. Kramer,et al.  Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  V. Chadha,et al.  Sieving coefficient inaccuracies during hemodiafiltration in patients with hyperbilirubinemia , 2000, Pediatric Nephrology.

[17]  M. Löhr,et al.  Liver support by extracorporeal blood purification: A clinical observation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  T. Risler,et al.  Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  V. Tripodi,et al.  Serum bile acids and pruritus in hemodialysis patients. , 2000, Clinical nephrology.

[20]  R. Vanholder,et al.  Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  M. Classen,et al.  Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. , 1999, Journal of hepatology.

[22]  Rahman,et al.  Review article: liver support systems in acute hepatic failure , 1999, Alimentary pharmacology & therapeutics.

[23]  M. Löhr,et al.  Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. , 1999, Artificial organs.

[24]  D. Falkenhagen,et al.  Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. , 1999, Artificial organs.

[25]  J. Stange,et al.  A Carrier-Mediated Transport of Toxins in a Hybrid Membrane. Safety Barrier between a Patients Blood and a Bioartificial Liver , 1996, The International journal of artificial organs.

[26]  A. Gimson,et al.  Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. , 1988, Gastroenterology.

[27]  S. Miyake,et al.  Bile acids of patients with renal failure receiving chronic hemodialysis , 1986, Steroids.

[28]  P. Jatlow,et al.  The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. , 1983, The New England journal of medicine.

[29]  L. Barbara,et al.  Quantitative aspects of the interaction of bile acids with human serum albumin. , 1982, Journal of lipid research.